Hikma Pharmaceuticals PLC (LON:HIK) Given Average Recommendation of “Buy” by Brokerages

Shares of Hikma Pharmaceuticals PLC (LON:HIK) have earned a consensus recommendation of “Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is GBX 2,060.

HIK has been the subject of a number of analyst reports. Citigroup increased their price target on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a “buy” rating in a report on Wednesday, August 12th. Jefferies Financial Group boosted their price objective on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Berenberg Bank upped their price objective on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 1,950 price objective on shares of Hikma Pharmaceuticals in a research note on Friday, August 7th.

Insiders Place Their Bets

In related news, insider Tobias Hestler purchased 7,500 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were bought at an average price of GBX 1,648 per share, for a total transaction of £123,600. Insiders own 22.04% of the company’s stock.

Hikma Pharmaceuticals Stock Performance

Hikma Pharmaceuticals stock opened at GBX 1,641 on Monday. The company’s 50-day moving average price is GBX 1,554.45 and its 200-day moving average price is GBX 1,456.08. The company has a quick ratio of 1.27, a current ratio of 1.98 and a debt-to-equity ratio of 77.57. The company has a market cap of £3.43 billion, a PE ratio of 9.07, a price-to-earnings-growth ratio of 2.38 and a beta of 0.66. Hikma Pharmaceuticals has a twelve month low of GBX 1,187 and a twelve month high of GBX 1,865.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.